TrialDiabetes, obesity & metabolism2018

Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.

David Polidori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.